The ALDH1A3 Knockout Jurkat Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population derived from Jurkat T cells, carrying targeted disruption of the ALDH1A3 gene. This bulk knockout model preserves cellular heterogeneity, averting clonal artifacts while enabling loss-of-function studies of ALDH1A3 in retinoic acid signaling. The polyclonal format is particularly suited for applications requiring average population responses, such as drug screens and pathway analyses.
Jurkat cells, an immortalized human T lymphocyte line from a T cell leukemia patient, are widely used to study T cell signaling, apoptosis, and HIV infection. Their well-defined genetic background and robust growth facilitate generation of gene-edited derivatives. The ALDH1A3 knockout Jurkat model provides a platform to assess retinoic acid metabolism in a leukemic T cell context, relevant to both immunology and cancer biology.
ALDH1A3 catalyzes NAD+-dependent oxidation of retinaldehyde to retinoic acid, which activates RAR/RXR nuclear receptor heterodimers. These directly regulate target genes including HOX, RAR??, and CYP26A1. Intracellular availability is modulated by CRABP1/2. Upstream, ALDH1A3 is controlled by FOXO3, ??-catenin, and HIF-1??, linking it to Wnt and hypoxia pathways. It also supports stemness factors SOX2 and OCT4. Consequently, ALDH1A3 knockout ablates retinoic acid synthesis, disrupting downstream transcriptional programs and enabling functional dissection of the pathway.
In Jurkat cells, ALDH1A3 knockout enables dissection of endogenous retinoic acid??s role in T cell activation, cytokine production, and apoptosis. Additionally, since ALDH activity is linked to chemoresistance in leukemia, this model can be used to explore ALDH1A3-mediated drug resistance and stem cell-like properties. The polyclonal nature ensures functional assessments capture a range of editing outcomes, avoiding single-clone biases that might obscure subtle phenotypic effects.
Key applications include ALDEFLUOR flow cytometry to verify ALDH activity loss, LC-MS-based retinoic acid quantitation, and expression analysis of downstream genes like RAR?? and CYP26A1 via RT-qPCR or Western blotting. The cells are suitable for drug sensitivity assays with ALDH inhibitors (e.g., DEAB) or retinoids, enabling drug target validation. Researchers can also employ them to study ALDH1A3??s contributions to cancer stem cell biology and developmental retinoid signaling. For additional information, please contact Ascent Research.
